Last updated on October 2016

Acne, psoriasis, atopic dermatitis


Brief description of study

Acne, psoriasis, atopic dermatitis

Detailed Study Description

A 52-week, multicenter, randomized, double-blind study of secukinumab (300mg) to demonstrate efficacy as assessed by psoriasis area and severity index and investigator's global assessment after 12 weeks of treatment, compared to ustekinumab, and to assess long-term safety, tolerability, and efficacy in subjects with moderate to severe plaque psoriasis.

Clinical Study Identifier: TX145538

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.